Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and Dementia. “Our late-stage asset, ATH-1017, is designed to act on a naturally occurring mechanism, known as hepatocyte growth factor (HGF) and its receptor, MET, to restore, rebuild and retain nerve […]

To train their students, medical schools often require actors to present symptoms of certain pathologies. Offering what is believed to be a more readily available and consistent alternative, the HAL S5301 robot is designed to simulate a patient with a brain injury. Produced by Miami-based Gaumard Scientific, the S5301 is a life-size adult humanoid robot, […]

The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment. A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenprodil precisely acts on the NMDA-type subunit 2B (GluN2B). The agency offered the feedback at the pre-Investigational New Drug (pre-IND) meeting for the therapy.